Wg. Christen et al., Blood levels off homocysteine and increased risks of cardiovascular disease - Causal of casual?, ARCH IN MED, 160(4), 2000, pp. 422-434
Citations number
102
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background: Accumulating data from epidemiological studies suggest that ind
ividuals with elevated blood levels of homocysteine have increased risks of
cardiovascular disease. We reviewed the currently available evidence of an
association between homocysteine and cardiovascular disease and examined w
hether the strength of the evidence Varies according to study design.
Methods: We used a computerized MEDLINE literature search, 1966 through Sep
tember 1998, to identify all epidemiological studies that examined the rela
tionship of homocysteine level with risks of coronary heart or cerebrovascu
lar disease. Two measures of plasma homocysteine level and its association
with risk of cardiovascular disease were extracted: mean homocysteine level
in cases and controls, and relative risk of cardiovascular disease for ele
vated homocysteine level.
Results: A total of 43 studies were reviewed. Most cross-sectional and case
-control studies indicated higher mean homocysteine levels (either fasting
or after methionine load) and/or a greater frequency of elevated homocystei
ne level in persons with cardiovascular disease as compared with persons wi
thout cardiovascular disease. Results of most prospective studies, however,
indicated smaller or no association. The few prospective studies that repo
rted a positive association between homocysteine level and risks of cardiov
ascular disease included patients with preexisting vascular disease.
Conclusions: In contrast to cross-sectional and case-control studies, resul
ts of prospective studies indicated less or no predictive ability for plasm
a homocysteine in cardiovascular disease. Instead, elevated homocysteine le
vel may be an acute-phase reactant that is predominantly a marker of athero
genesis, or a consequence of other factors more closely linked to risks of
cardiovascular disease. Randomized trials are necessary to test reliably wh
ether lowering homocysteine levels will decrease risks of cardiovascular di
sease.